(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Europe’s EV Boom Was Real in 2025. The Real Fight Starts In 2026 - 2UN chief warns he could refer Israel to ICJ over laws targetting UNRWA
- 3Instructions to Decide whether a Fender bender Legal counselor is Required for Your Particular Case
- 4What's Your #1 Pizza Beating Mix?
- 5Red Crescent: More than 100,000 civilian structures damaged in Iran
- 4 Family SUVs: Joining Solace and Style
- Unwind: Four Extraordinary Spa Resorts On the planet
- Going on a bad date is a drag. Worse? Ending up as a cautionary tale on TikTok.
- Private sector revives the climate disaster database Trump tried to squash
- Reporter's Notebook: The Post embeds with foreign armies visiting the IDF
- Brexit's Effect on New York's Ascent as a Main Monetary Center
- This Week In Space podcast: Episode 187 — An Inspired Enterprise
- As cases of a rare, deadly infection rise, doctors worry fewer teens will get vaccinated
- From Overpowered to Coordinated: Individual Accounts of Cleaning up
